PRLD — Prelude Therapeutics Incorporated Share News
0.000.00%
Last trade - 00:00- $236.22m
- $84.47m
- $12.14m
Brief: Prelude Therapeutics Announces Q3 Financial Results And Provides Business Update
Prelude Therapeutics Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Prelude Therapeutics Receives FDA Clearance Of Ind For Prt3789
Prelude Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Prelude Therapeutics Posts Cash And Cash Equivalents Of $246.3 Mln As Of June 30, 2022, Expected To Fund Operations Into Second Half Of 2024
Prelude Therapeutics Inc expected to post a loss of 61 cents a share - Earnings Preview
Prelude Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Prelude Therapeutics Posts Q1 Loss Per Share $0.63
Prelude Therapeutics Inc expected to post a loss of 65 cents a share - Earnings Preview
Prelude Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Prelude Therapeutics Reports Full Year 2021 Financial Results
Prelude Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
Brief: Prelude Therapeutics Provides Clinical Update
Brief: Jane Huang, M.D. Joins Prelude Therapeutics As President And Chief Medical Officer
Brief: Prelude Therapeutics Inc Files For Mixed Shelf Of Up To $400 Million – SEC Filing
Prelude Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Prelude Therapeutics Q3 Loss Per Share $0.66
Brief: Prelude Therapeutics Announced Q3 Results
U.S. STOCKS ON THE MOVE-Peloton, AMD, Coty, eHealth, 51job, Tesla